Dr. Gregory A. Demopulos is the President and CEO of Omeros Corporation, a leading company in biotechnology that focuses on developing innovative therapeutic drugs. Holding an M.D. from the University of Washington and a B.S. in Biology from UC San...

Dr. Gregory A. Demopulos is the President and CEO of Omeros Corporation, a leading company in biotechnology that focuses on developing innovative therapeutic drugs. Holding an M.D. from the University of Washington and a B.S. in Biology from UC San Diego, he has both medical and scientific expertise. Since he co-founded Omeros in 1994, Dr. Demopulos has played a significant role in advancing its drug programs, specifically in pain management and inflammation. His commitment to both the company and his medical practice sets him apart; he remains an active surgeon and has a solid background in orthopedic and hand surgery. His compensation reflects the company's performance, with a total package of around $950,000 in 2023 amidst escalating company growth metrics. Notably, his stock holdings peaked at approximately $34 million in late 2019, highlighting his personal investment in the company's success. He has also strategically navigated insider trades, displaying a deep understanding of market conditions. Dr. Demopulos emphasizes long-term value creation both for the company and its shareholders, aligning his work with Omeros' mission to offer effective treatments while building a sustainable biotech business.